Type of security: Stock
Sector: Health Care
Industry: Medical/Dental Instruments
The data is delayed by 15 minutes.
ALQA is in the long-term down -96% in 7 years.
Description: Alliqua, Inc., a biomedical company, focuses on the development, manufacture, and distribution of proprietary transdermal wound care and drug delivery technologies. The company provides water content, electron beam cross-linked, and aqueous polymer hydrogels for use in wound care, medical diagnostics, transdermal drug delivery, and cosmetics. Its products include SilverSeal, a hydrogel wound dressing with silver coated fibers; and Hydress, an over-the-counter hydrogel wound dressing. The company also develops HepaMate, an extracorporeal temporary liver support system designed to provide whole liver function to patients with acute or severe liver failure. It has a license, marketing, and development agreement with Anthrogenesis Corporation for the development and commercialization of Extracellular Matrix and Biovance products. Alliqua, Inc. is headquartered in Langhorne, Pennsylvania.
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||-0.72||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||103.86%||Sales Growth - Q/Q||27.04%||P/E||-0.51|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-98.06%||ROE||-142.18%||ROI|
|Current Ratio||3.33||Quick Ratio||2.97||Long Term Debt/Equity||Debt Ratio||0.26|
|Gross Margin||39.02%||Operating Margin||-385.83%||Net Profit Margin||-381.53%||Dividend Payout Ratio|
|Cash From Financing Activities||50 K||Cash From Investing Activities||-10 K||Cash From Operating Activities||-5.88 M||Gross Profit||730 K|
|Net Profit||-7.66 M||Operating Profit||-7.68 M||Total Assets||24.55 M||Total Current Assets||14.76 M|
|Total Current Liabilities||4.43 M||Total Debt||290 K||Total Liabilities||7.62 M||Total Revenue||2.11 M|
|High 52 week||2.72||Low 52 week||1.63||Last close||1.63||Last change||-2.4%|
|RSI||41.46||Average true range||0.1||Beta||0.07||Volume||172.59 K|
|Simple moving average 20 days||-4.39%||Simple moving average 50 days||-18.72%||Simple moving average 200 days||-22.4%|
|Performance Week||-3.55%||Performance Month||-7.91%||Performance Quart||-38.51%||Performance Half||-20.87%|
|Performance Year||-26.91%||Performance Year-to-date||-9.94%||Volatility daily||3.24%||Volatility weekly||7.24%|
|Volatility monthly||14.83%||Volatility yearly||51.37%||Relative Volume||957.42%||Average Volume||14.74 K|
|New High||New Low|
2019-04-22 10:06:35 | Alliqua BioMedical CEO Provides Update to Shareholders
2019-04-11 16:49:02 | Alliqua BioMedical Declares Contingent Special Dividend of $1.05 per Share and Announces Record Date for the Contingent Special Dividend and the Spin-Off of Contract Manufacturing Business
2019-01-03 07:00:00 | Alliqua Biomedical CEO Provides Update to Shareholders
2018-12-27 07:35:00 | New Research: Key Drivers of Growth for Zillow Group, Woodward, Navistar International, Multi-Color, Ferrellgas Partners, and Alliqua BioMedical — Factors of Influence, Major Initiatives and Sustained Production
2018-12-14 10:25:00 | What to Watch as Healthcare Stocks Continue to Outperform the Market
2018-11-30 15:28:35 | Trade The Market, Not Your Expectations
2018-11-28 14:19:21 | Cannabis Connection Sends Alliqua Shares Soaring Nearly 200%
2018-11-28 07:30:00 | Alliqua BioMedical to spin off and merge its Contract Manufacturing Business with TO Pharmaceuticals LLC to Create an Independent, Publicly Traded Company focused on Cannabinoid-Based Pharmaceutical Therapies
2018-10-29 09:00:00 | Consolidated Research: 2018 Summary Expectations for Green Brick Partners, Alliqua BioMedical, Buckle, DaVita, CDK Global, and Mylan N.V — Fundamental Analysis, Key Performance Indications
2018-09-28 08:20:00 | New Research Coverage Highlights Employers, Alliqua BioMedical, Express Scripts Holding, CF Industries, Nutanix, and Coca-Cola — Consolidated Revenues, Company Growth, and Expectations for 2018
2018-09-14 10:49:06 | How Does Investing In Alliqua BioMedical Inc NASDAQ:ALQA Impact Your Portfolio?
2018-06-27 09:30:29 | Is There Now An Opportunity In Alliqua BioMedical Inc NASDAQ:ALQA?
2018-06-11 08:00:00 | Investor Expectations to Drive Momentum within Gorman-Rupp, Mistras Group, Inovalon, Johnson Controls International plc, Best Buy Co., and Alliqua BioMedical — Discovering Underlying Factors of Influence
2018-05-07 16:15:00 | Alliqua BioMedical, Inc. Announces Closing Asset Sale to Celularity Inc.
2018-05-01 13:46:15 | Want To Invest In Alliqua BioMedical Inc NASDAQ:ALQA? Here’s How It Performed Lately
2018-03-31 16:39:23 | Are Alliqua BioMedical Inc’s NASDAQ:ALQA Interest Costs Too High?
2018-03-22 10:38:10 | Should You Buy Alliqua BioMedical Inc NASDAQ:ALQA At $1.84?
2018-01-31 07:40:00 | Analysis: Positioning to Benefit within Alliqua BioMedical, Donegal Group, QAD, ManpowerGroup, Acorda Therapeutics, and Arena Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
2017-11-09 18:38:33 | Edited Transcript of ALQA earnings conference call or presentation 9-Nov-17 1:00pm GMT
2017-11-09 07:55:30 | Alliqua reports 3Q loss
2017-11-09 06:00:00 | Alliqua, Inc. to Host Earnings Call
2017-10-17 19:31:19 | Is It Time To Buy Alliqua BioMedical Inc ALQA?
2017-10-05 16:01:00 | Alliqua BioMedical, Inc. Announces 1-for-10 Reverse Stock Split
2017-09-21 18:15:09 | Have Investors Already Priced In Alliqua BioMedical Inc’s ALQA Growth?
2017-09-05 19:50:19 | ETFs with exposure to Alliqua BioMedical, Inc. : September 5, 2017
2017-09-05 18:25:11 | [$$] The Add-On Deal Roundup: Sept. 5
2017-08-10 23:54:59 | Alliqua reports 2Q loss
2017-08-10 18:47:42 | Edited Transcript of ALQA earnings conference call or presentation 10-Aug-17 12:00pm GMT
2017-08-10 07:00:00 | Alliqua BioMedical, Inc. Reports Second Quarter of Fiscal Year 2017 Financial Results